[ad_1]
Regeneron Pharmaceuticals (NASDAQ: REGN) is still frequently framed through one question: how much pressure will EYLEA face from competition, biosimilars, and the transition to EYLEA HD? That question matters, but it no longer captures the whole investment story. Regeneron has become a more diversified cash-generation platform in which retinal disease, immunology, oncology, collaboration economics, and pipeline optionality all contribute to value. Investors who look only at the EYLEA franchise risk missing how much of Regeneron’s earnings power now sits outside that single debate.
The first quarter of 2026 made that clear. Regeneron reported total revenue of $3.605 billion, up 19% year over year, while non-GAAP diluted EPS rose 15% to $9.47. Total net product sales increased 8% to $1.535 billion, but the bigger story was in the composition of revenue. Sanofi collaboration revenue climbed 36% to $1.605 billion, Bayer collaboration revenue contributed $287 million, and other revenue more than doubled to $171 million. The company ended the quarter with $18.54 billion in cash and marketable securities, giving it unusual balance-sheet flexibility for a large-cap biotech.
That revenue mix matters because it shows Regeneron is not dependent on one commercial asset or one business model. Product sales still matter, but collaboration income now represents a large and growing source of earnings power. That changes how investors should think about durability. A biotech tied to one mature blockbuster can look vulnerable when competitive dynamics shift. A biotech with multiple revenue streams, a strong partner economics model, and substantial cash reserves looks more capable of absorbing franchise transitions while continuing to invest.
The EYLEA franchise itself is a good example of why the headline debate can be misleading. In the first quarter, EYLEA HD U.S. net sales increased 52% to $468 million, while legacy EYLEA U.S. sales fell 36% to $473 million. Combined EYLEA HD and EYLEA U.S. sales declined 10% to $941 million. If an investor stops there, the takeaway may be that retinal-disease revenue is simply under pressure. But that view misses the internal shift taking place. Regeneron said EYLEA HD sales were driven by higher demand, and although reported EYLEA HD net sales fell 7% sequentially, physician unit demand increased 10% sequentially. In other words, the transition is not just erosion. It is also a mix shift toward a newer product with differentiated dosing potential.
That distinction matters because it changes the question from “Is EYLEA falling?” to “Can EYLEA HD offset pressure in a way that preserves the franchise’s economic value while the rest of the company grows?” The answer is not settled, but it is clearly more nuanced than a simple decline narrative. Regeneron also noted that a settlement with Samsung Bioepis means the company will not market an aflibercept biosimilar in the United States until January 2027, which gives the franchise more runway than a worst-case reading might imply.
More importantly, the rest of the company is already getting bigger. Dupixent global net sales, recorded by Sanofi, increased 33% to $4.9 billion in the quarter, helping drive Regeneron’s Sanofi collaboration revenue sharply higher. That matters because Dupixent is one of the best examples in large-cap biotech of how a collaboration can create recurring, high-quality economics beyond what shows up in direct product sales. Libtayo adds another layer. Global Libtayo sales rose 54% to $438 million, with U.S. sales up 49% and rest-of-world sales up 63%.
This is where the thesis becomes broader than ophthalmology. Immunology and oncology are now meaningful contributors to Regeneron’s financial profile, not just pipeline hopes. The company also said it has nearly 50 product candidates in clinical development, including additional indications for marketed products. At the same time, management reiterated a capital allocation approach built around internal innovation, shareholder returns, manufacturing expansion, and strategic flexibility. In the quarter, the board authorized a new $3.0 billion share repurchase program, and full-year 2026 capital spending guidance was revised to $1.1 billion to $1.2 billion.
Those decisions are backed by real financial capacity. A company with more than $18 billion in cash and marketable securities can fund R&D, absorb manufacturing issues, repurchase stock, and still remain opportunistic on business development. That matters because biotech durability is often about more than the current portfolio. It is about whether the company can keep turning today’s cash flows into tomorrow’s products without weakening the balance sheet.
There are still things to watch closely. Regeneron said GAAP gross margin on net product sales was pressured by unabsorbed manufacturing costs and higher inventory write-offs tied to a temporary interruption at its Limerick, Ireland facility, though production resumed in the second quarter. Competition in retinal disease is real, and investors should not assume EYLEA HD automatically neutralizes every risk. Collaboration revenue can also be strong and still remain partly dependent on partner execution. But those are risks inside a much broader engine than the market sometimes credits.
Regeneron’s investment case is increasingly about portfolio balance. The company still needs to manage the EYLEA transition well, but it is also collecting growing economics from Dupixent, building oncology scale with Libtayo, investing behind a deep pipeline, and operating from a position of exceptional financial strength. That is a more durable setup than a one-product narrative suggests.
Key Signals for Investors
- First-quarter 2026 revenue growth of 19% and non-GAAP EPS growth of 15% show that Regeneron’s earnings power is expanding even while the EYLEA franchise is in transition.
- Combined EYLEA and EYLEA HD sales declined, but EYLEA HD itself grew 52% year over year and physician demand improved sequentially, which suggests the retinal story is more mix-driven than purely deteriorating.
- Sanofi collaboration revenue of $1.605 billion and global Libtayo sales of $438 million show that immunology and oncology are already meaningful contributors to the cash engine.
- With $18.54 billion of cash and marketable securities, a new $3.0 billion buyback authorization, and higher capital-spending guidance, Regeneron has the financial capacity to keep investing through product transitions.
Sources
- https://www.sec.gov/Archives/edgar/data/872589/000087258926000014/exhibit991q12026.htm
- https://www.sec.gov/Archives/edgar/data/872589/000087258926000016/regn-20260331.htm
- https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm
[ad_2]
Source link